Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Genetics Pulls In $106K in Q3 Revenues

NEW YORK (GenomeWeb News) – Atossa Genetics reported after the close of the market on Thursday $105,576 in revenues for the third quarter compared to no revenues in the year-ago period.

For the three months ended Sept. 30, revenues were comprised of $104,011 in Diagnostic Testing Services and $1,565 in product sales. The Seattle-based firm launched ForeCYTE and ArgusCYTE tests a year ago and said today that it expects to roll out the tests nationally in early 2013.

Atossa said that its SG&A spending retreated 3 percent to $1.23 million from $1.27 million a year ago.

Its net loss was $1.1 million, or $.10 per share, in Q3 2012, compared to a net loss of $1.3 million, or $.11 per share, a year ago.

The company ended the quarter with $418,570 in cash and cash equivalents.

Atossa went public a month ago, raising $4 million in gross proceeds. Proceeds from its initial public offering will be used to accelerate the national launch of its US Food and Drug Administration-cleared ForeCYTE test for breast cancer risk assessment, Steven Quay, chairman, president, and CEO of Atossa, said in a statement.

Atossa was founded in 2009 by Quay, who invented its flagship technology called Mammary Aspirate Specimen Cytology Test System, or MASCT, a device and method for the collection, shipment, and clinical analysis of nipple aspirate fluid which contains cells and biomarkers that may be used to detect breast cancer and cellular changes that may be associated with the disease.

MASCT is the backbone of tests being developed by the company.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.